Stock futures are modestly positive this morning. Markets are stabilizing and leaning cautiously higher as investors shift from escalation fears to tentative optimism around renewed U.S.-Iran diplomacy. Crude has slipped back below the $100 level as signals emerge that both sides are considering another round of negotiations, easing immediate supply fears tied to the Strait of Hormuz. Global markets are higher, with U.S. indices pushing back toward pre-war levels, supported by tech strength and early earnings from major banks. However, the U.S. naval blockade is still in place, oil flows remain disrupted, and the broader energy shock has not been resolved.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
In pre-market trading, S&P 500 futures rose 0.27%, Nasdaq futures rose 0.53% and Dow futures rose 0.07%.
Check out this morning’s top movers from around Wall Street, compiled by The Fly.
HIGHER –
- Globalstar (GSAT) up 11% after entering into a definitive merger agreement under which Amazon (AMZN) will acquire the company for $90.00 per share
- American Airlines (AAL) and United Airlines (UAL) up 8% and 2%, respectively, after Bloomberg reported United Airlines CEO Scott Kirby has floated a potential merger with American
- Novo Nordisk (NVO) up 3% after announcing a strategic partnership with OpenAI to speed drug development
UP AFTER EARNINGS –
DOWN AFTER EARNINGS –
LOWER –
- Clearmind Medicine (CMND) down 33% after reporting that CMND-100, the company’s non-hallucinogenic MEAI-based oral drug candidate for the treatment of Alcohol Use Disorder, has met the primary endpoint in its Phase I/IIa clinical trial
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Clearmind Medicine announces CMND-100 meets primary endpoint
- Psychedelic: Clearmind completes treatment, follow-up for CMND-100 trial
- Clearmind Medicine completes treatment, follow-up in CMND-100 trial
- Clearmind files patent application in India for psychedelic-based compounds
- Psychedelic: AtaiBeckley reports publication of BPL-003 study results
